-
Modern antidiabetics, such as SGLT2 inhibitors, have shown positive effects on cardiovascular risks or kidney function for diabetics. However, recent study results show an equal benefit for heart failure patients regardless of their diabetes status.
-
Prof. Casadei talks about what the cardiology field has learnt from the COVID-19 crisis, what positive aspects have emerged from it, and how to turn the profession back into a vocation.
-
The early practice of rhythm control reduces cardiovascular outcomes in patients with early atrial fibrillation and comorbid cardiovascular conditions compared to current evidence-based standard care.
-
Recent studies on heart failure treatment showed that SGLT2 inhibitors reduced the risk of cardiovascular death or even hospitalization in heart failure, with reduced ejection fraction compared to placebo.
-
The cardiovascular risk in diabetes is determined by some comorbidities. Renal dysfunction and micro- and macrovascular events are common. Should diabetes patients be screened for cardiovascular risks?
-
Tumour treatment with drugs often leads to a rapid loss of strength in patients and increases their cardiovascular risk and general mortality. Accompanying physical training can mitigate these effects.
-
A research team developed an innovative antibody for chronic anemia treatment in dialysis patients. It allows for a lower EPO dose and the resulting minimization of cardiovascular risk.
-
According to a recent study, the movements and breathing during yoga have a positive influence on the symptoms in patients with atrial fibrillation.
-
Just send a selfie to the cardiologist and receive a heart disease risk assessment. Sounds futuristic? It could actually become routine, according to a recent study.
-
Dr. Vikramjeet Singh is investigating how the interaction of intestinal bacteria and immune cells influences a brain infarction, with a particular focus on microbial diversity in the intestine, and neutrophils.
-
Hepatitis-C eradication by 2030, as required by the WHO, is within reach in Spain. Dr. Joaquin Cabezas explains how the country is making prisons HCV-free by near 100% diagnosis and 100% treatment.
-
NAFLD is a form of fatty liver (steatosis hepatitis) not caused by increased alcohol consumption. The prevalence in Europe is estimated to be between 20 and 30%.
-
Scientists have developed effective antimicrobial glass and basalt fibers. The fibers are effective against different strains of bacteria and fungi and might be used in filters and textiles in the future.
-
Chronic liver disease is on the rise. Aside from undetected liver disease, abnormal liver function tests are often not followed up in primary care, or many patients ignore their follow-up appointments.
-
Hepatitis E represents a major health challenge worldwide and is still difficult to control. For example, prevention in disinfection is reaching its limits and vaccination is currently only available in China.
-
How does COVID-19 affect patients with liver disease? This was the topic of a special online session at the EASL digital congress 2020.
-
HIV coinfection is quite common in HCV patients. However, little research has been done on the influence of such co-infections on the morbidity and mortality of those affected.
-
With the help of the Europe-wide PREDICT study, an international research association determined three forms of acute decompensated liver cirrhosis.
-
Researchers identified a microRNA in obese female mice that transmit a potential risk of liver cancer to their offspring over generations.
-
Repeated measurement of the FIB-4 index score over several years helps to assess the risk of developing a serious liver disease such as cirrhosis, according to a recent study from Sweden.
